Marshall Financial Group LLC Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Marshall Financial Group LLC decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 32.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 648 shares of the pharmaceutical company’s stock after selling 312 shares during the period. Marshall Financial Group LLC’s holdings in Vertex Pharmaceuticals were worth $314,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of VRTX. Mascagni Wealth Management Inc. purchased a new position in Vertex Pharmaceuticals in the fourth quarter valued at approximately $31,000. Truvestments Capital LLC lifted its stake in Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock valued at $40,000 after purchasing an additional 23 shares during the last quarter. Mpwm Advisory Solutions LLC purchased a new position in Vertex Pharmaceuticals in the fourth quarter valued at approximately $40,000. Midwest Capital Advisors LLC purchased a new position in Vertex Pharmaceuticals in the fourth quarter valued at approximately $41,000. Finally, Minot DeBlois Advisors LLC purchased a new position in Vertex Pharmaceuticals in the fourth quarter valued at approximately $44,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the topic of several recent research reports. Scotiabank dropped their target price on Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating on the stock in a research report on Tuesday, May 6th. Wolfe Research downgraded Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, May 7th. Leerink Partners restated a “market perform” rating and set a $503.00 target price (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. JPMorgan Chase & Co. increased their target price on Vertex Pharmaceuticals from $512.00 to $515.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Fourteen analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $515.04.

Vertex Pharmaceuticals Stock Down 1.0%

VRTX opened at $455.45 on Friday. The stock has a market cap of $116.96 billion, a PE ratio of -207.02, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The business’s fifty day simple moving average is $462.54 and its 200 day simple moving average is $460.16.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). The firm had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company earned $4.76 EPS. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.